|
AU2004259638C1
(en)
|
2003-07-08 |
2018-12-20 |
Novartis Pharma Ag |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
|
WO2010048415A1
(en)
*
|
2008-10-22 |
2010-04-29 |
Cedars-Sinai Medical Center |
Methods of using jak3 genetic variants to diagnose and predict crohn's disease
|
|
WO2008101133A2
(en)
*
|
2007-02-14 |
2008-08-21 |
Cedars-Sinai Medical Center |
Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
|
|
US20100021455A1
(en)
*
|
2004-12-08 |
2010-01-28 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of crohn's disease
|
|
US7910703B2
(en)
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
AU2007260787A1
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc |
IL-17 and IL-23 antagonists and methods of using the same
|
|
ES2373069T3
(es)
|
2006-08-11 |
2012-01-31 |
Schering Corporation |
Anticuerpos para il-17a.
|
|
US8414897B1
(en)
|
2006-10-02 |
2013-04-09 |
The Uab Research Foundation |
Pathway for Th-17 cell development and methods utilizing same
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Ｉｌ-２３拮抗劑於治療感染之用途
|
|
EP2064242A1
(en)
|
2007-02-23 |
2009-06-03 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
|
ATE554791T1
(de)
*
|
2007-02-23 |
2012-05-15 |
Schering Corp |
Gentechnisch hergestellte anti-il-23p19- antikörper
|
|
WO2008106451A2
(en)
*
|
2007-02-26 |
2008-09-04 |
Cedars-Sinai Medical Center |
Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
|
|
WO2008106579A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Cedars-Sinai Medical Center |
The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
|
|
AU2008219681A1
(en)
|
2007-02-28 |
2008-09-04 |
Merck Sharp & Dohme Corp. |
Combination therapy for treatment of immune disorders
|
|
WO2010039931A2
(en)
*
|
2008-10-01 |
2010-04-08 |
Cedars-Sinai Medical Center |
Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
|
|
US20100015156A1
(en)
*
|
2007-03-06 |
2010-01-21 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel disease in children
|
|
WO2008116150A2
(en)
|
2007-03-21 |
2008-09-25 |
Cedars-Sinai Medical Center |
Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
|
|
US20100184050A1
(en)
*
|
2007-04-26 |
2010-07-22 |
Cedars-Sinai Medical Center |
Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
|
|
CA2683145C
(en)
|
2007-04-27 |
2018-06-12 |
Katherine E. Lewis |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
|
US20100144903A1
(en)
*
|
2007-05-04 |
2010-06-10 |
Cedars-Sinai Medical Center |
Methods of diagnosis and treatment of crohn's disease
|
|
US9305137B1
(en)
|
2007-05-18 |
2016-04-05 |
Cedars-Sinai Medical Center |
Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
|
|
JP5424330B2
(ja)
*
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
|
US20100203009A1
(en)
*
|
2007-10-02 |
2010-08-12 |
The Uab Research Foundation |
Pathway for Th-17 Cell Development and Methods Utilizing Same
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
WO2009120922A2
(en)
*
|
2008-03-27 |
2009-10-01 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
|
SG10201608871XA
(en)
|
2008-05-05 |
2016-12-29 |
Novimmune Sa |
Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
WO2010019565A2
(en)
*
|
2008-08-12 |
2010-02-18 |
Medlmmune, Llc |
Anti-ephrin b2 antibodies and their use in treatment of disease
|
|
WO2010027766A1
(en)
|
2008-08-27 |
2010-03-11 |
Schering Corporation |
Lyophilized formulatons of engineered anti-il-23p19 antibodies
|
|
US8790642B2
(en)
*
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
WO2010056816A2
(en)
*
|
2008-11-12 |
2010-05-20 |
Schering Corporation |
βGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
|
|
US20110229471A1
(en)
*
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
|
WO2010071800A1
(en)
|
2008-12-19 |
2010-06-24 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
|
WO2010075579A2
(en)
|
2008-12-24 |
2010-07-01 |
Cedars-Sinai Medical Center |
Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
|
|
CA2759848C
(en)
|
2009-05-05 |
2018-12-04 |
Novimmune S.A. |
Anti-il-17f antibodies and methods of use thereof
|
|
EA020621B1
(ru)
|
2009-06-22 |
2014-12-30 |
Амген Инк. |
Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
|
|
JP2012531428A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
AU2010291985B2
(en)
|
2009-09-14 |
2016-05-05 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
|
JO3244B1
(ar)
*
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
CN102905727B
(zh)
|
2009-10-30 |
2016-12-07 |
詹森生物科技公司 |
Il-17a拮抗剂
|
|
GB201013975D0
(en)
|
2010-08-20 |
2010-10-06 |
Imp Innovations Ltd |
Method of treating desease
|
|
WO2011079004A1
(en)
|
2009-12-23 |
2011-06-30 |
Schering Corporation |
Cell line 3m
|
|
EA201892184A1
(ru)
|
2010-03-01 |
2019-03-29 |
БАЙЕР ХЕЛЬСКЕР ЛЛСи |
Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
|
|
US20130011406A1
(en)
*
|
2010-03-26 |
2013-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
EP2635601B1
(en)
|
2010-11-04 |
2016-07-20 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
JP6058645B2
(ja)
|
2011-06-10 |
2017-01-11 |
メディミューン，エルエルシー |
抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
|
|
USRE49026E1
(en)
|
2011-06-14 |
2022-04-12 |
Medical Diagnostic Laboratories, Llc |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
US8946150B2
(en)
|
2011-06-14 |
2015-02-03 |
Medical Diagnostic Laboratories, LLC. |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
EP2583979B1
(en)
*
|
2011-10-19 |
2015-12-16 |
Effimune |
Methods to prepare antibodies directed against p19 subunit of human IL-23
|
|
SMT202000542T1
(it)
|
2011-11-07 |
2020-11-10 |
Medimmune Ltd |
Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
|
|
US9284283B2
(en)
|
2012-02-02 |
2016-03-15 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating IL-17
|
|
WO2013165791A1
(en)
|
2012-05-03 |
2013-11-07 |
Boehringer Ingelheim International Gmbh |
Anti-il-23p19 antibodies
|
|
US8945553B2
(en)
|
2012-05-22 |
2015-02-03 |
Bristol-Myers Squibb Company |
Bispecific antibodies to IL-23 and IL-17A/F
|
|
SG11201407806YA
(en)
*
|
2012-05-31 |
2014-12-30 |
Agency Science Tech & Res |
Mixed multifunctional metal affinity surfaces for reducing aggregate content in protein preparations field
|
|
WO2014004436A2
(en)
|
2012-06-27 |
2014-01-03 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
|
WO2014018625A1
(en)
|
2012-07-25 |
2014-01-30 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
WO2014055999A2
(en)
*
|
2012-10-05 |
2014-04-10 |
Kadmon Corporation, Llc |
Treatment of ocular disorders
|
|
CN105007939B
(zh)
*
|
2012-10-05 |
2018-10-19 |
卡德门企业有限公司 |
人抗vegfr-2/kdr抗体
|
|
US9273093B2
(en)
|
2012-10-11 |
2016-03-01 |
Protagonist Therapeutics, Inc. |
α4β7 peptide dimer antagonists
|
|
EP3441400B1
(en)
*
|
2012-11-19 |
2022-07-20 |
Pieris Pharmaceuticals GmbH |
Novel specific-binding polypeptides and uses thereof
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AU2014228553B2
(en)
|
2013-03-15 |
2019-01-24 |
Amgen Inc. |
Methods for treating Crohn's disease using an anti-IL23 antibody
|
|
EP4091624A1
(en)
|
2013-03-15 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Hepcidin analogues and uses thereof
|
|
US20160060337A1
(en)
|
2013-03-15 |
2016-03-03 |
Amgen Inc. |
Methods for treating psoriasis using an anti-il-23 antibody
|
|
JP6671276B2
(ja)
|
2013-03-27 |
2020-03-25 |
セダーズ−シナイ メディカル センター |
Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
|
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
CA2949215C
(en)
|
2014-05-16 |
2023-03-14 |
Protagonist Therapeutics, Inc. |
.alpha.4.beta.7 integrin thioether peptide antagonists
|
|
US10774119B2
(en)
|
2014-05-22 |
2020-09-15 |
Pieris Pharmaceuticals Gmbh |
Specific-binding polypeptides and uses thereof
|
|
US10239943B2
(en)
|
2014-05-23 |
2019-03-26 |
Celldex Therapeutics, Inc. |
Treatment of eosinophil or mast cell related disorders
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AU2015291123C1
(en)
*
|
2014-07-14 |
2020-12-10 |
Gennova Biopharmaceuticals Limited |
A novel process for purification of rHu-GCSF
|
|
EP4378536A3
(en)
|
2014-07-17 |
2024-10-09 |
Protagonist Therapeutics, Inc. |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
EP3172339A1
(en)
|
2014-07-24 |
2017-05-31 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
US10059763B2
(en)
|
2014-09-03 |
2018-08-28 |
Boehringer Ingelheim International Gmbh |
Compound targeting IL-23A and TNF-alpha and uses thereof
|
|
SG11201702553RA
(en)
|
2014-10-01 |
2017-04-27 |
Protagonist Therapeutics Inc |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
EP3201217A4
(en)
|
2014-10-01 |
2018-07-18 |
Protagonist Therapeutics Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
AR102417A1
(es)
|
2014-11-05 |
2017-03-01 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-tnf- / anti-il-23
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
IL307578A
(en)
|
2015-02-04 |
2023-12-01 |
Boehringer Ingelheim Int |
Methods of treating inflammatory diseases
|
|
CA2977499C
(en)
|
2015-02-25 |
2023-10-03 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
|
EP3265493B1
(en)
|
2015-03-02 |
2024-01-10 |
180 Therapeutics LP |
Method of treating a localized fibrotic disorder using an il-33 antagonist
|
|
CA2977534A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
|
CA2986713A1
(en)
*
|
2015-05-22 |
2016-12-01 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for a prame peptide
|
|
MA41010B1
(fr)
*
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
CN116672446A
(zh)
|
2015-09-17 |
2023-09-01 |
美国安进公司 |
使用il23途径生物标志物预测il23拮抗剂的临床应答
|
|
BR112018010766A8
(pt)
|
2015-11-27 |
2019-02-26 |
Csl Ltd |
proteínas de ligação ao cd131 e usos das mesmas
|
|
BR112018012626A2
(pt)
|
2015-12-22 |
2018-12-04 |
Amgen Inc |
ccl20 como um preditor de resposta clínica a antagonistas de il23
|
|
WO2017117411A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
US11186872B2
(en)
|
2016-03-17 |
2021-11-30 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through RNASET2
|
|
CN115925790A
(zh)
|
2016-03-23 |
2023-04-07 |
领导医疗有限公司 |
用于合成α4β7肽拮抗剂的方法
|
|
WO2017205820A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Affinity matured broad spectrum antibodies to hepatitis c virus
|
|
US9611297B1
(en)
*
|
2016-08-26 |
2017-04-04 |
Thrasos Therapeutics Inc. |
Compositions and methods for the treatment of cast nephropathy and related conditions
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
WO2018204374A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
EP4092038A1
(en)
|
2017-09-11 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Opioid agonist peptides and uses thereof
|
|
CA3089868A1
(en)
|
2018-02-08 |
2019-08-15 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
EP3773717A4
(en)
*
|
2018-03-29 |
2022-05-11 |
REMD Biotherapeutics, Inc. |
TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
|
|
SG11202100185VA
(en)
|
2018-07-13 |
2021-02-25 |
Astrazeneca Collaboration Ventures Llc |
Treating ulcerative colitis with brazikumab
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
KR20220044277A
(ko)
|
2019-07-10 |
2022-04-07 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
|
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
|
WO2021146454A1
(en)
|
2020-01-15 |
2021-07-22 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2021146441A1
(en)
|
2020-01-15 |
2021-07-22 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20220206001A1
(en)
*
|
2020-10-22 |
2022-06-30 |
Twist Bioscience Corporation |
Methods and systems for detecting coronavirus
|
|
EP4247403A4
(en)
|
2020-11-20 |
2024-12-11 |
JANSSEN Pharmaceutica NV |
COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
|
|
JP2024525732A
(ja)
|
2021-07-14 |
2024-07-12 |
ヤンセン バイオテツク，インコーポレーテツド |
インターロイキン－２３受容体の脂質化ペプチド阻害剤
|
|
WO2023122211A2
(en)
*
|
2021-12-21 |
2023-06-29 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
WO2024119065A2
(en)
*
|
2022-12-02 |
2024-06-06 |
Jecho Laboratories, Inc. |
Anti-mesothelin bispecific antibodies and methods of use
|
|
WO2025071335A1
(ko)
*
|
2023-09-27 |
2025-04-03 |
삼성바이오에피스 주식회사 |
항-il-17 항체의 안정한 액상 제형
|